

Testicular (Germ Cell) Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maint

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (select all that apply)

Platinum-refractory or resistant? __Yes __No __Not Reported

Seminoma | Stage II-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Seminoma | Stage III B-C | Good and Intermediate Risk | Metastatic Disease

BEP: bleomycin, etoposide (Toposar), and cisplatin*

Nonseminoma | Stage II-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Nonseminoma | Stage III B-C | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Adjuvant Therapy after RPLND†

EP: etoposide (Toposar) and cisplatin

*BEP is typically given for 3 cycles in good risk seminoma, and 4 cycles in intermediate risk

†RPLND: Retroperitoneal lymph node dissection

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 05/22/2018 | Effective date: 06/29/2018

Appropriate.Safe.Affordable

© 2018 AIM Specialty Health
9022-0618